Foundation Fighting Blindness

Foundation Fighting Blindness

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

Episodes

October 2, 2025 3 mins
The emerging therapy improved vision for some participants in an earlier clinical trial.
Mark as Played
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
Mark as Played
Lance Baldo, MD, CEO at Beacon Therapeutics, talks to host Ben Shaberman about his company's fully enrolled Phase 3 VISTA clinical trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa (RPGR mutations) that's showed promising results in earlier trials. They also discuss Beacon's forthcoming clinical trial for its dry age-related macular degeneration gene therapy.
Mark as Played
The documentary “Aggie: An Incredible Story of Art and Justice” chronicles her story.
Mark as Played
NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
Mark as Played
September 5, 2025. Dr. George Magrath, CEO of Opus Genetics, talks with host Ben Shaberman about the company's evolution and progress in clinically developing gene therapies for several inherited retinal diseases including those caused by mutations in the genes: LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1.
Mark as Played
The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
Mark as Played
The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
Mark as Played
August 8, 2025. Dr. Christina Ohnsman talks to host Ben Shaberman about Tern Therapeutics, a start-up company she co-founded to develop gene therapies for Batten disease and potentially other conditions. Dr. Ohnsman reviews early results for a Batten disease (CLN2) retinal gene therapy clinical trial. She also reflects on her previous work as a pediatric ophthalmologist and roles with Spark Therapeutics and Regenxbio.
Mark as Played
Susvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule
Mark as Played
July 25, 2025. Dr. Christine Curcio, one of the world's foremost experts in age-related macular degeneration (AMD) pathogenesis and the associated risk of advanced vision loss, talks to host Ben Shaberman about her epical career and recent Proctor Medal lecture with Dr. Cynthia Owsley at the 2025 meeting of the Association for Eye and Vision Research (ARVO). Her work has led to a highly effective test for predicting who is at great...
Mark as Played
The therapy delivers copies of the RORA gene to address multiple disease pathways.
Mark as Played
The company plans to complete BLA submission in early 2026.
Mark as Played
July 11, 2025. Richard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The therapy is a tiny, implantable capsule, the size of a rice grain, that delivers neurotrophic factors to preserve the patient's retinal cells and vision. The approach was previously developed to treat retinitis pigmentosa and age-r...
Mark as Played
The expanded Phase 1/2/3 shortens time to potential FDA approval.
Mark as Played
June 13, 2025. Dr. Philip Beales, a co-founder of Axovia Therapeutics, talks to host Ben Shaberman about Bardet Biedl syndrome, ciliopathies, and his company's emerging gene therapy for Bardet Biedl syndrome type 1 (BBS1) which is moving toward a clinical trial.
Mark as Played
May 23, 2025. Lenore von Krusenstiern, MD, PhD, at BlueRock Therapeutics talks to host Ben Shaberman about the company's clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy. The approach, which uses induced pluripotent stem cells to develop photoreceptor precursors, comes out of the lab of stem cell pioneer David Gamm, MD, PhD, Unive...
Mark as Played
Despite missing the primary endpoint, the treatment improved vision for some patients.
Mark as Played
The company is planning a Phase 2/3 clinical trial for therapy in late 2025.
Mark as Played
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
Mark as Played

Popular Podcasts

    If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

    Dateline NBC

    Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

    The Joe Rogan Experience

    The official podcast of comedian Joe Rogan.

    On Purpose with Jay Shetty

    I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!

    The Bobby Bones Show

    Listen to 'The Bobby Bones Show' by downloading the daily full replay.

Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2025 iHeartMedia, Inc.